Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) gapped down before the market opened on Wednesday . The stock had previously closed at $15.81, but opened at $15.40. Centessa Pharmaceuticals shares last traded at $14.83, with a volume of 116,993 shares traded.
A number of research analysts recently weighed in on CNTA shares. Morgan Stanley reaffirmed an "overweight" rating and issued a $27.00 price target on shares of Centessa Pharmaceuticals in a research note on Friday, March 7th. Guggenheim reissued a "buy" rating and set a $28.00 target price on shares of Centessa Pharmaceuticals in a report on Wednesday. Finally, TD Cowen started coverage on Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They issued a "buy" rating on the stock. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $26.00.
Get Our Latest Report on CNTA
The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. The company has a fifty day moving average price of $16.51 and a two-hundred day moving average price of $16.43. The firm has a market capitalization of $1.93 billion, a price-to-earnings ratio of -9.58 and a beta of 1.54.
Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.34) earnings per share for the quarter, topping analysts' consensus estimates of ($0.38) by $0.04. As a group, research analysts forecast that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.
In related news, insider Gregory M. Weinhoff sold 10,000 shares of the company's stock in a transaction that occurred on Thursday, December 26th. The stock was sold at an average price of $17.04, for a total value of $170,400.00. Following the transaction, the insider now directly owns 183,266 shares in the company, valued at approximately $3,122,852.64. This represents a 5.17 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, General Counsel Iqbal J. Hussain sold 6,000 shares of the stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $15.29, for a total value of $91,740.00. Following the completion of the transaction, the general counsel now owns 118,265 shares of the company's stock, valued at $1,808,271.85. The trade was a 4.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 260,168 shares of company stock valued at $4,316,568. 11.59% of the stock is currently owned by insiders.
Several hedge funds have recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD lifted its holdings in shares of Centessa Pharmaceuticals by 14.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,364,392 shares of the company's stock worth $89,854,000 after acquiring an additional 685,371 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its stake in Centessa Pharmaceuticals by 22.0% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,119,027 shares of the company's stock worth $85,744,000 after purchasing an additional 924,027 shares in the last quarter. Janus Henderson Group PLC lifted its stake in Centessa Pharmaceuticals by 279.2% during the fourth quarter. Janus Henderson Group PLC now owns 4,909,487 shares of the company's stock worth $82,218,000 after purchasing an additional 3,614,623 shares in the last quarter. Farallon Capital Management LLC grew its stake in shares of Centessa Pharmaceuticals by 24.3% in the fourth quarter. Farallon Capital Management LLC now owns 3,498,709 shares of the company's stock valued at $58,603,000 after buying an additional 684,391 shares in the last quarter. Finally, Point72 Asset Management L.P. grew its stake in shares of Centessa Pharmaceuticals by 26.2% in the fourth quarter. Point72 Asset Management L.P. now owns 3,426,599 shares of the company's stock valued at $57,396,000 after buying an additional 710,936 shares in the last quarter. Hedge funds and other institutional investors own 82.01% of the company's stock.
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Centessa Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Centessa Pharmaceuticals wasn't on the list.
While Centessa Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.